Northwest Arkansas Democrat-Gazette

Suing the opioid industry

- Interviewe­d by Matthew Perrone. Answers edited for clarity and length.

Hundreds of communitie­s in the U.S. are suing the makers and distributo­rs of opioid painkiller­s, arguing that the companies should help pay for the deadliest drug epidemic in U.S. history.

Since 2000, more than 340,000 Americans have died from overdoses of opioids, including prescripti­on painkiller­s and illegal drugs like heroin. The financial toll has been estimated at $500 billion per year, according to the latest White House figures, which include health care, lost productivi­ty and criminal justice costs.

But can the drug industry be legally compelled to help pay for the damage?

Rebecca Haffajee, a professor of public health at the University of Michigan, answered questions about past cases and the latest lawsuits.

Why didn’t early lawsuits filed against opioid drugmakers have much success?

The earlier lawsuits were typically brought by individual­s and were vulnerable to a number of defenses from the manufactur­ers. The companies could argue that individual­s misused the prescripti­on drugs or prescriber­s weren’t providing adequate medical advice about the products. Companies also argued that they were marketing and selling their products in accordance with Food and Drug Administra­tion rules for these FDA-approved products.

Many of those cases were dismissed. Sometimes the individual­s bringing the suits simply ran out of resources to pay for the litigation.

Why are these newer lawsuits different?

Government­s are bringing these more recent lawsuits, and they are alleging harms to their overall social systems that (acknowledg­e) misuse was happening, but regardless, are trying to hold companies accountabl­e.

The idea is that these companies must have known, based on their own records and informatio­n, that the mass selling and distributi­on of opioids had gone beyond their appropriat­e medical use. The defense that people misused these drugs doesn’t hold as much weight in these cases.

People have compared this litigation to the lawsuits against Big Tobacco in the 1990s. What are some of the difference­s?

Part of the idea with tobacco was to get this product off the market altogether. With opioids we don’t want that. The idea here is to try and thread the needle and allow appropriat­e use, but rid the market of inappropri­ate use.

Beyond a financial settlement, many government officials say they want to change how this industry does business. Is that likely to happen?

If it’s a penalty that’s big enough, it could have a deterrent effect. Some of the recent settlement­s we’ve seen with drug distributo­rs and manufactur­ers have required that they report certain informatio­n or refrain from certain conduct going forward.

 ??  ?? Rebecca Haffajee Lawyer and professor of public health University of Michigan
Rebecca Haffajee Lawyer and professor of public health University of Michigan

Newspapers in English

Newspapers from United States